China's medical institutions and British enterprises sign a memorandum of strategic cooperation

[chinapharma.com.int'l news] on June 14, GlaxoSmithKline, a British pharmaceutical company, announced that it has signed a memorandum of strategic cooperation with Guangzhou respiratory disease research institute, and plans to establish a health big data system covering different levels of medical institutions, medical insurance payment and management systems in the field of asthma and chronic obstructive pulmonary disease respiratory treatment (picture source of strategic cooperation memorandum signed by Chinese medical institutions and British Enterprises: Baidu picture) the strategic cooperation includes two parts: prospective registration research of chronic obstructive pulmonary disease and "comfortable breathing" online management platform for Chinese asthma patients Among them, the prospective COPD study will cover about 5000 patients Relevant data will help to study the burden of COPD on China and promote the introduction of corresponding management strategies Chen Rongchang, director of Guangzhou Institute of respiratory diseases, said that working with GlaxoSmithKline can understand the new research concept, promote the transformation of medical achievements, change the traditional diagnosis and treatment mode, enable grassroots patients to enjoy advanced diagnosis and treatment methods, and provide academic basis for health and medical insurance decision-making and the establishment of individualized treatment strategies suitable for grassroots Wei Liansheng, general manager of China prescription medicine and vaccine Department of GlaxoSmithKline, said he hoped the cooperation could provide valuable data, improve the health of Chinese people, improve the level of basic medical treatment and promote the development of hierarchical diagnosis and treatment.